AbbVie Inc - Research and Development

AbbVie Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Research-and-Development" stands at 13.18 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

AbbVie Inc's third quarter result of 2.24 Billion USD for the item "Research and Development" represents an increase of 6.86 percent compared to it's second quarter result.

Also, AbbVie Inc's third quarter result of 2.24 Billion USD for the item "Research and Development" represents an increase of 5.35 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), AbbVie Inc's third quarter result of 13.18 Billion USD for the item "Research and Development" represents an increase of 0.87 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 60.28 percent compared to the value the year prior.
The 1 year change in percent is 60.28.
The 3 year change in percent is 79.00.
The 5 year change in percent is 83.10.
The 10 year change in percent is 222.45.

The Serie's long term average value is 6.33 Billion United States Dollars. It's latest available value, on 09/30/2025, is 108.37 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2011, to it's latest available value, on 09/30/2025, is +403.72%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.